Salvatore Siena

Also affiliated with Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system”.

Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system

Transfusion(1999)10.1046/j.1537-2995.1999.39199116894.x

N/A

4.5DataRank · unranked

49 citations

Salvatore Siena, Stefan De Reys, Massimo Di Nicola, Paola Notti, Roberto Giardini +5 more

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Nature Medicine(2022)10.1038/s41591-022-01931-y

N/A

3.9DataRank · unranked

240 citations

Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido +14 more

Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).

Journal of Clinical Oncology(2013)10.1200/jco.2013.31.15_suppl.3617

N/A

0.568DataRank · unranked

43 citations

Marc Peeters, Salvatore Siena, Eric Van Cutsem, Yves Humblet, Jean-Luc Van Laethem +5 more

Immunocytokines in cancer treatment: A systematic review

Cancer Treatment Reviews(2025)10.1016/j.ctrv.2025.102978

N/A

0.312DataRank · unranked

7 citations

Chiara Veronese, Ferdinando Panzeri, Simonetta Palazzini, Greta Guarnieri, Stefano Loiacono +15 more

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer

The Oncologist(2023)10.1093/oncolo/oyad210

N/A

0.250DataRank · unranked

3 citations

Rona Yaeger, Jean‐Pierre Delord, Josep Tabernero, Lillian L. Siu, Michel Ducreux +9 more

540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

Annals of Oncology(2020)10.1016/j.annonc.2020.08.654

N/A

0.104DataRank · unranked

1 citations

Filippo de Braud, Alexander Drilon, Robert C. Doebele, Manish R. Patel, Byoung Chul Cho +15 more

Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer

Clinical Lung Cancer(2023)10.1016/j.cllc.2023.12.001

N/A

0DataRank · unranked

5 citations

Alexander Drilon, Chao‐Hua Chiu, Herbert H. Loong, Salvatore Siena, Maciej Krzakowski +5 more

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0187

N/A

0DataRank · unranked

493 citations

Rona Yaeger, Pamela Arcella, Carlotta Cancelliere, Simona Lamba, Annalisa Lorenzato +24 more

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial

ESMO Open(2025)10.1016/j.esmoop.2025.105892

N/A

0DataRank · unranked

0 citations

Salvatore Siena, A. Sartore-Bianchi, Javier Ros, F. Ciardello, E. Martinelli +38 more